The path to personalized medicine

Bouchard, 1995, The genetics of obesity: from genetic epidemiology to molecular markers, Mol Med Today, 1, 45, 10.1016/1357-4310(95)80020-4 Los, 1999, The importance of genetic influences in asthma, Eur Respir J, 14, 1210, 10.1183/09031936.99.14512109 Kahn, 1996, Genetics of non-insulin-dependent (type-II) diabetes mellitus, Annu Rev Med, 47, 509, 10.1146/annurev.med.47.1.509 Day, 2001, Science, medicine, and the future: genetics and cardiovascular risk, BMJ, 323, 1409, 10.1136/bmj.323.7326.1409 Vaisse, 1998, A frameshift mutation in human MC4R is associated with a dominant form of obesity, Nat Genet, 20, 113, 10.1038/2407 Altshuler, 2000, The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes, Nat Genet, 26, 76, 10.1038/79839 Brinkman, 1997, Tumour necrosis factor alpha gene polymorphisms in rheumatoid arthritis: association with susceptibility to, or severity of, disease?, Br J Rheumatol, 36, 516, 10.1093/rheumatology/36.5.516 Sachidanandam, 2001, A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms, Nature, 409, 928, 10.1038/35057149 Patil, 2001, Blocks of limited haplotype diversity revealed by high-resolution scanning of human chromosome 21, Science, 294, 1719, 10.1126/science.1065573 Stephens, 2001, Haplotype variation and linkage disequilibrium in 313 human genes, Science, 293, 489, 10.1126/science.1059431 Ridker, 1999, Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women, Circulation, 98, 731, 10.1161/01.CIR.98.8.731 Rost, 2001, Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study, Stroke, 32, 2575, 10.1161/hs1101.098151 Mallal, 2002, Association between presence of HLA-B*5701, HLA-DR7, and HLA-Dq3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir, Lancet, 359, 727, 10.1016/S0140-6736(02)07873-X Fellay, 2002, Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study, Lancet, 359, 30, 10.1016/S0140-6736(02)07276-8 Ioannidis, 2001, Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3′A alleles on HIV-1 disease progression: an international meta-analysis of individual-patient data, Ann Intern Med, 135, 782, 10.7326/0003-4819-135-9-200111060-00008 Drazen, 1999, Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment, Nat Genet, 22, 168, 10.1038/9680 Drysdale, 2000, Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness, Proc Natl Acad Sci USA, 97, 10483, 10.1073/pnas.97.19.10483 Petricoin, 2002, Use of proteomic patterns in serum to identify ovarian cancer, Lancet, 359, 572, 10.1016/S0140-6736(02)07746-2 Duncan, 2001, Melastatin expression and prognosis in cutaneous malignant melanoma, J Clin Oncol, 19, 568, 10.1200/JCO.2001.19.2.568 Hartmann LC, Couch FJ, Kaufmann SH, Cliby WA, Iturria SJ, Kalli KR, Lu K, Bast B, Lillie J, Stec J et al.: Chemoprediction in Ovarian Cancer – Genomic Approaches. Society of Gynecological Oncologists, 33rd Annual meeting: 2002 March 16–20; Miami Beach, Florida. [http://www.sgo.org/meetings/33annual/default.htm] Oestreicher, 2001, Molecular classification of psoriasis disease-associated genes through pharmacogenomic expression profiling, Pharmacogenomis, 1, 272, 10.1038/sj.tpj.6500067